FDA approves Sagent's bacitracin for pneumonia and empyema
Links shared publicly online about this topic.
- 1,172total visits
FDA approves Sagent's bacitracin for pneumonia and empyema
Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced FDA approval of bacitracin for injection, USP (bacitracin), an anti-infective product used to treat pneumonia and empyema. Bacitracin will be offered in a 50,000 MU, AP-rated, preservative-free, latex-free, single-dose vial packaged both individually and in packages of ten.
View full resource at news-medical.net
Most Recently Shared on May 13, 2010 at 4:46 am By:
FDA approves Sagent's bacitracin for pneumonia and empyema: Sagent Pharmaceuticals, Inc., a privately held special... http://bit.ly/b1TeIw
Advertisement
